

Supplemental Online Content

The Writing Committee for the COMEBAC Study Group. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. *JAMA*. Published online March 17, 2021.
doi:10.1001/jama.2021.3331

Table of contents

List of symptoms evaluated at telephone consultation	3
Questionnaire administered during telephone consultation	3
Pulmonary function tests.....	6
Dysfunctional breathing.....	6
Nijmegen questionnaire.....	7
Lung CT scan.....	7
Supplementary table 1. Tests used for psychological, cognitive and respiratory evaluation	8
Supplementary table 2. Baseline and hospitalization characteristics of patients who did not have the telephone assessment and of patients who had the telephone assessment according to their intubation status during the hospital stay	9
Supplementary table 3. Baseline and hospitalization characteristics and results of the telephone assessment in the 177 patients who attended the ambulatory visit compared to the 117 patients who did not.....	11
Supplementary table 4. Baseline and hospitalization characteristics of the patients who had the telephone assessment classified by symptoms triggering the visit to the outpatient facility.....	13
Supplementary table 5. Results of the telephone assessment and of the ambulatory visit depending on age (< 75 vs. ≥ 75 yr).....	15
Supplementary table 6. Results of the telephone assessment classified by symptoms triggering the visit to the outpatient facility	17
Supplementary table 7. Results of the ambulatory visit classified by symptoms triggering the visit to the outpatient facility	18
Supplementary figure 1. Visualization of symptoms* and their overlap presented by the 192 patients (out of 478 patients) who presented at least one symptom at teleconsultation.....	19
Supplementary figure 2. Results of the 36-item Short-Form Health Survey (SF-36) and Multidimensional Fatigue Inventory (MFI-20 scale) scores of the patients admitted to the outpatient clinic	20

Supplementary figure 3. Anti-SARS-CoV-2 serological index of the patients admitted to the outpatient clinic.....	22
References.....	23
Collaborators.....	24

This supplemental material has been provided by the authors to give readers additional information about their work.

List of symptoms evaluated at telephone consultation

General signs

- Anorexia
- Fatigue
- New hospitalization
- Weight loss

Respiratory signs

- New-onset dyspnea
- Chest discomfort, chest pain
- New-onset cough
- Abnormal lung CT-scan since discharge

Neurologic signs

- Headache
- Paresthesia
- Anosmia
- Limb palsy

Cognitive signs

- Memory losses
- Slowness for reasoning, activity planification or problem solving
- Concentration, attention difficulties

Questionnaire administered during telephone consultation

Consent

Date of the teleconsultation: [date]

Consultant name: [Consultant name]

Patient identity: [First name] [Last name], [Date of birth], [Calculated age] years

Was admitted in the following departments: [admission department]

My name is [Consultant name] and I work at Bicêtre hospital. You were admitted in [admission department] for COVID-19 three months ago.

We call you today to organize your follow-up.

If you agree, I will ask you some questions that will be used to orientate your needs of medical follow-up specific to your COVID-19 infection.

May I continue this interview? [YES / NO]

If no, why? [text]

Is-it the patient him/herself? [YES / NO]

If not, who is the respondent [First name] [Last name], [phone number] and relationship to the patient [Spouse, Children, Sibling, Neighbor/Friend, Care giver]

Has the patient died since discharge? [YES / NO]

If yes, where has the patient died? [Home, Rehabilitation facility, Retirement home, Other hospital inpatient, Other] [date of death] and [cause of death]

General inquiry

Do you speak French? [YES / NO]

If not, what language do you speak? [Text]

If not, can someone of your household assist you for the teleconsultation? [YES / NO]
 If not, can someone of your household assist you for the day hospital? [YES / NO]
 Do you have an insurance? [YES / NO]

On the [date of discharge], you were discharged from Bicêtre hospital. Where did you go? [Home, Rehabilitation facility, Retirement home, Other hospital, Other].

When did you get home? [date]

Are you working at the moment? [YES / NO]

If yes, since when? [date]

What do you do? [Text]

Did you have a significant medical event since your discharge? [YES / NO]

If yes, what was it? [text] When was it? [date]

If yes, were you admitted in a hospital for this event? [YES / NO]

If yes, did you consult a physician? [YES / NO]

If yes, whom? [Text]

If yes, did you do any laboratory or radiologic examination? [YES / NO]

Did you modify your usual treatment since discharge? [YES / NO]

Where do you live now? [Home, Relative, Rehabilitation facility, Retirement home, Other]

Were you living there prior to your hospitalization for COVID19? [YES / NO]

If yes, where were you living prior to your hospitalization for COVID19? [Home, Relative, Rehabilitation facility, Retirement home, Other]

How much did you weigh before your admission? [text]

How much did you weigh when you were discharged? [Text]

How much do you currently weigh? [Text]

Do you have a new and persistent anorexia since your hospitalization?

[YES / NO]

Do you have a new and persistent fatigue since your hospitalization? [YES / NO]

Respiratory symptoms

In his/her chart, is the patient known to have had a pulmonary embolism during his stay? [YES / NO]

Do you feel abnormally breathless at rest or when active? [YES / NO]

If yes, did you feel the same prior to your hospitalization? [YES / NO]

How would you rate your dyspnea [mMRC scale 0 to 5]

Do you feel heaviness, pain or chest discomfort at rest or when active? [YES / NO]

If yes, did you feel the same prior to your hospitalization? [YES / NO]

Do you cough every day? [YES / NO]

If yes, was it the same prior to your hospitalization? [YES / NO]

Did you do a chest CT scan since your discharge as it may have been prescribed at your discharge? [YES / NO]

If yes, when [date]?

What was the result? [Normal/Abnormal]

Do you have a CD with the images? [YES / NO]

Neurological symptoms

In his/her chart, is the patient known to have had an abnormal brain MRI during his stay? [YES / NO]

In his/her chart, is the patient known to have had an abnormal brain EEG during his stay? [YES / NO]

Do you have a new and persistent anosmia since your hospitalization? [YES / NO]

Do you have new and persistent headaches since your hospitalization? [YES / NO]

If yes, on a scale from 1 to 10, 0 being no pain at all and 10 being the worst you could imagine, how much would you rate your headaches related pain? [1-10]

What medication do you take for your headaches? [Text]

Do you have new and persistent paresthesia since your hospitalization? [YES / NO]

Do you have new and persistent burn-like or electric-like pain since your hospitalization? [YES / NO]

Do you have new and persistent loss of function of one of your limbs since your hospitalization? [YES / NO]

Cognitive disorder screening (Q3PC)

During the last 2 weeks, and significantly more than previously, do you:

- Have memory losses (for eg., Missed an appointment, forgotten a recent event, or misplaced a daily object)?
 [Rarely: less than once a week; Sometimes: once a week; Often: Several times a week but not every day; Very often: Almost all the time]

- Feel like you were slower for reasoning, activity planification or problem solving?
 [Rarely: less than once a week; Sometimes: once a week; Often: Several times a week but not every day; Very often: Almost all the time]

- Experience difficulties to concentrate or muster your attention (for eg., follow a conversation, read the paper or follow a tv program)?
 [Rarely: less than once a week; Sometimes: once a week; Often: Several times a week but not every day; Very often: Almost all the time]

Elderly

Regarding corporeal hygiene, do you have:

- [Total autonomy / Partial help / Dependent]
- Deterioration since the hospitalization for COVID19: [YES / NO]

Regarding dressing, do you have:

- [Total autonomy for clothes choice and dressing / Autonomy for clothes choice and dressing, but requires help for / Dependent]
- Deterioration since the hospitalization for COVID19: [YES / NO]

Regarding bathroom use, do you have:

- [Total autonomy for undressing and dressing / Requires help for undressing or dressing / Dependent]
- Deterioration since the hospitalization for COVID19: [YES / NO]

Regarding locomotion, do you have:

- [Total autonomy / Partial help / Bedridden]
- Deterioration since the hospitalization for COVID19: [YES / NO]

Regarding continence, do you have:

- [Continent / Occasional incontinence / Incontinent]
- Deterioration since the hospitalization for COVID19: [YES / NO]

Regarding meals, do you:

- [Eats alone/ Requires help for service, cutting the meat or peeling a fruit/ Dependent]
- Deterioration since the hospitalization for COVID19: [YES / NO]

Does the patient have 3 or more deterioration in the score? [YES / NO]

Do you have any helping at home? [YES / NO]

Did you fell since your hospitalization? [YES / NO]

If yes, how many times? [Number]

If more than twice, are you under a physiotherapist care? [YES / NO]

Has the patient lost more than 5kg since discharge? [YES / NO]

Did the patient report an altered general state with association of asthenia, anorexia and weight loss? [YES / NO]

Nephrology

Do you have a known renal disease (e.g., renal transplant recipient, on hemodialysis or any renal chronic condition)?
 [YES / NO]

In his/her chart, what is the patient's last known creatinine level and glomerular filtration rate before discharge?
 [Text]

Ethics

We would like to inform you that your personal data, recorded during this teleconsultation may be used for medical research under the responsibility of the *Assistance publique-hôpitaux de Paris*. You can refuse now, or any time by contacting us, your primary doctor at the hospital or the data protection officer at the hospital.

Information was given and the patient did not express refusal: [YES / NO]

Pulmonary function tests

Patients completed standard pulmonary function tests (PFTs) with spirometry, whole-body plethysmography and single-breath diffusing lung capacity for carbon monoxide (DLCO) according to the ERS/ATS guidelines ¹⁻³. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), total lung capacity (TLC) and DLCO were expressed as percentages of predicted values using GLI 2012 and ECCS 1993 equations ^{4,5}.

Dysfunctional breathing

Hyperventilation provocation test (HVPT) was based on a methodology previously described ⁶ and performed using a turbine flowmeter and a face mask (Cosmed, Italy). HPVT was considered positive if at least two daily symptoms were reproduced and/or if an abnormal breathing pattern was identified (i.e hyperventilation and/or periodic deep sighing as defined elsewhere ⁷). Diagnosis of dysfunctional breathing was confirmed if the score of Nijmegen questionnaire was ≥ 23 and the HPVT was positive.

Nijmegen questionnaire

How often do you suffer from the symptoms listed? Please score each item from 0 to 4:

0: never; 1: rarely; 2: sometimes; 3: often; 4: very often

Symptoms	Score (from 0 to 4)
Chest pain	
Feeling tense	
Blurred vision	
Dizzy spells	
To be confused, losing touch with environment	
Accelerated or deepened breathing	
Shortness of breath	
Constricted chest	
Bloated abdominal sensation	
Unable to breathe deeply	
Tingling fingers	
Stiffness of fingers or arms	
Tightness around the mouth	
Cold hands or feet	
Palpitations	
Anxiety	
Total score	/64

A score > 22 suggests dysfunctional breathing.

Lung CT scan

All images were acquired at the end of inhalation using a 2 x 128 -row CT scanner (Somatom Flash, Siemens, Erlangen, Germany). Acquisition parameters were set as follows: tube voltage of 120 kV, automatic tube current modulation of 100–300 mA, pitch of 0.5 mm, matrix of 512 × 512, slice thickness of 1.0 mm. All images were then reconstructed with a slice of 1.0 mm with the same increment in mediastinal and parenchymal windows.

Supplementary table 1. Tests used for psychological, cognitive and respiratory evaluation

Test	Self evaluation (Yes/No)	Symptom Assessed	Best score	Worst score	Chosen diagnostic cut-off
European AIDS Clinical Society cognitive screening questions (Q3PC) ⁸	No	Memory difficulties/mental slowness/concentration problems	N/A	N/A	≥1 positive answer
SF36 ⁹		8 dimensions of general health	0	100	No cut-off value
MFI20	Yes	4 dimensions of fatigue	5	0	No cut-off value
Beck Depression Inventory 13 items (BDI-13) ¹¹	Yes	Depression	0	39	>7
Hamilton Anxiety and Depression scale - Anxiety (HAD-A) ¹²	Yes	Anxiety	0	21	>7
Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5) ¹³	Yes	Post Traumatic Stress	0	80	>30
Insomnia Severity Index ¹⁴ (ISI)	Yes	Insomnia	0	28	>7
Montreal Cognitive Assessment (MoCA) scale ¹⁵	No	Global cognitive functioning	30	0	<21 to <25*
Mac NAIR ¹⁶	Yes	Memory Complaint	0	156	>54 to >66**
d2-R ¹⁷	No	Attention	135	65***	<76
Nijmegen questionnaire ⁷	No	Dysfunctional breathing	0	64	>22

* depends on age and educational level

** depends on age

*** mean score is 100 with standard deviation of 15

Supplementary table 2. Baseline and hospitalization characteristics of patients who did not have the telephone assessment and of patients who had the telephone assessment according to their intubation status during the hospital stay

	Patients who had the telephone consultation			Patients who did not have the telephone consultation (n=673)
	All patients (N=478)	Non-intubated patients (n=405)	Intubated patients (n=73)	
Age, years, mean (SD)	60.9 (16.1)	61.4 (17.0)	58.4 (10.1)	67.7 (20.7)
Women/men No. (%)	201 (42.1)/ 277 (57.9)	183 (45.2)/ (54.8)	222 (24.7)/ 55 (73.3)	305 (45.3)/ 368 (54.7)
Body mass index, kg/m², mean (SD) [No.]	28.8 (5.6) [351]	28.6 (5.8) [281]	29.5 (4.9) [70]	
Comorbidities, No. (%)				
Hypertension	225 (47.1)	183 (45.2)	42 (57.5)	
Obesity, No./total (%)	130/351 (37.0)	98/281 (34.9)	32/70 (45.7)	
Diabetes mellitus	128 (26.8)	101 (24.9)	27 (37.0)	
Chronic heart disease	77 (16.1)	69 (17.0)	8 (11.0)	
Respiratory disease (other than COPD)	75 (15.7)	68 (16.8)	7 (9.59)	
Chronic kidney disease	51 (10.7)	41 (10.1)	10 (13.7)	
Declared psychiatric disorder	42 (8.8)	35 (8.6)	7 (9.6)	
Neurodegenerative disorder	34 (7.1)	34 (8.4)	0 (0.0)	
Alcohol abuse, No./total (%)	21/450 (4.7)	17/382 (4.5)	4/68 (5.6)	
Active cancer	18 (3.8)	16 (4.0)	2 (2.7)	
Other immunosuppression	18 (3.8)	15 (3.7)	3 (4.1)	
COPD	17 (3.6)	15 (3.7)	2 (2.7)	
Chronic dialysis	17 (3.6)	13 (3.2)	4 (5.5)	
HIV infection	12 (2.5)	10 (2.5)	2 (2.7)	
Solid organ transplantation	9 (1.9)	6 (1.5)	3 (4.1)	
Liver disease	7 (1.5)	6 (1.5)	1 (1.4)	
Pregnancy	5 (1.1)	4 (1.0)	1 (1.4)	
Bone marrow transplantation	2 (0.4)	1 (0.3)	1 (1.4)	
Smoking, No./total (%)				
No (<5 PY)	343/452 (75.9)	293/383 (76.5)	50/69 (72.5)	
Former (> 5 PY)	83/452 (18.4)	73/383 (19.1)	10/69 (14.5)	
Active	26/452 (5.8)	17/383 (4.4)	9/69 (13.0)	
Specific treatments, No. (%)				
Azithromycin	120 (25.1)	98 (24.2)	22 (30.1)	
Tocilizumab (anti-IL6)	37 (7.7)	23 (5.7)	14 (19.2)	
Hydroxychloroquine	32 (6.7)	20 (4.9)	12 (16.4)	
Supplementary table 2 (continued)	Patients who had the telephone consultation			Patients who did not have

	All patients (N=478)	Non-intubated patients (n=405)	Intubated patients (n=73)	the telephone consultation (n=673)
Specific treatments, No. (%)				
Corticosteroids	24 (5.0)	13 (3.2)	11 (15.1)	
Lopinavir/Ritonavir	16 (3.4)	11 (2.7)	5 (6.9)	
Anakinra (anti-IL1RA)	11 (2.3)	8 (2.0)	3 (4.1)	
Remdesivir	5 (1.1)	5 (1.2)	0 (0.0)	
Vasopressors, No. (%)	74 (15.5)	10 (2.5)	64 (87.7)	
Active anticoagulation (at full therapeutic dose), No. (%)	75 (15.7)	48 (11.9)	27 (37.0)	
Pulmonary embolism during hospitalization, No. (%)				
	41 (8.6)	29 (7.2)	12 (16.4)	
Acute kidney injury during hospitalization, No. (%)				
	95 (19.9)	58 (14.3)	37 (50.7)	
Hospitalization in ICU, No. (%)	142 (29.7)	69 (17.0)	73 (100)	276 (24.0)
Duration of ICU stay, days, median [Q1;Q3]	9 [4;19]	4 [3;6]	18 [11;32]	
Total duration of hospitalization, days, median [Q1;Q3]	9 [4;15]	8 [4;12]	27 [17;49]	

COPD: chronic obstructive pulmonary disease, ECMO: extracorporeal membrane oxygenation, HIV: human immunodeficiency virus, ICU: intensive care unit, PY: pack year.

Supplementary table 3. Baseline and hospitalization characteristics and results of the telephone assessment in the 177 patients who attended the ambulatory visit compared to the 117 patients who did not

	Attended the ambulatory visit (n=177)	Did not attend the ambulatory visit (n=117)
Baseline and hospitalization characteristics		
Age, years	56.9 (13.2)	66.3 (17.5)
Women/men No. (%)	68 (38.4)/109 (61.6)	49 (41.9)/68 (58.1)
Body mass index, kg/m², mean (SD) [No.]	29.1 (5.4) [165]	28.8 (5.6) [77]
Comorbidities, No. (%)		
Hypertension	75 (42.4)	62 (53.0)
Obesity, No./total (%)	67/165 (40.6)	28/77 (36.4)
Diabetes mellitus	52 (29.4)	33 (28.2)
Chronic heart disease	14 (7.91)	30 (25.6)
Respiratory disease (other than COPD)	30 (16.9)	20 (17.1)
Chronic kidney disease	17 (9.60)	16 (13.7)
Declared psychiatric disorder	12 (6.78)	14 (12.0)
Neurodegenerative disorder	2 (1.13)	18 (15.4)
Alcohol abuse, No./total (%)	9/168 (5.4)	5/109 (4.6)
Active cancer	3 (1.7)	8 (6.8)
Other immunosuppression	7 (4.0)	5 (4.3)
COPD	5 (2.8)	6 (5.1)
Chronic dialysis	6 (3.4)	5 (4.3)
HIV infection	3 (1.7)	5 (4.3)
Solid organ transplantation	4 (2.3)	3 (2.6)
Liver disease	5 (2.8)	1 (0.9)
Pregnancy	2 (1.1)	2 (1.7)
Bone marrow transplantation	0 (0)	0 (0)
Smoking, No./total (%)		
No (<5 PY)	129/169 (76.3)	83/110 (75.5)
Former (> 5 PY)	25/169 (14.8)	23/110 (20.9)
Active	15/169 (8.9)	4/110 (3.6)
Specific treatments, No. (%)		
Azithromycin	53 (29.9)	29 (24.8)
Tocilizumab (anti-IL6)	27 (15.3)	4 (3.4)
Hydroxychloroquine	18 (10.2)	8 (6.4)
Corticosteroids	7 (4.0)	10 (8.6)
Lopinavir/Ritonavir	8 (4.5)	3 (2.6)
Anakinra (anti-IL1RA)	8 (4.5)	1 (0.9)
Remdesivir	3 (1.7)	0 (0.0)
Pressors use	51 (28.8)	18 (15.4)
Therapeutic anticoagulation	49 (27.7)	17 (14.5)
Pulmonary embolism during hospitalization, n (%)	29 (19.1)	10 (9.26)
Acute kidney injury during hospitalization, n (%)	57 (32.2)	43 (36.8)
Hospitalization in ICU, No. (%)	97 (54.8)	38 (32.5)

Supplementary table 3 (continued)	Attended the ambulatory visit (n=177)	Did not attend the ambulatory visit (n=117)
Duration of ICU stay, days	9.00 [4.00;22.0]	8.00 [4.00;16.0]
Total duration of hospitalization, days	13.0 [6.00;23.0]	9.00 [6.00;13.0]
Telephone consultation^a		
Time from hospital discharge to teleconsultation, days median [IQR] (No.)	104 [86.8;120]	114 [96.0;128]
Anosmia, No./total (%)	16 (10.5)	5 (4.7)
Headaches, No./total (%)	14 (9.2)	8 (7.5)
Paresthesia, No./total (%)	37 (24.3)	11 (10.3)
Anorexia	17/164 (10.4)	13/108 (12.0)
Fatigue	78/165 (47.3)	32/104 (30.8)
Weight loss >5% baseline weight	10/148 (6.8)	6/78 (7.7)
Chest discomfort/pain	23/151 (15.2)	8/106 (7.6)
Cough	11/152 (7.2)	9/106 (8.5)
Limb palsy	19/150 (12.7)	16/107 (15.0)
Memory difficulties (Q3PC questionnaire ^b), No./total (%)	33/152 (21.7)	34/103 (33.0)
Mental slowness (Q3PC questionnaire ^b), No./total (%)	22/152 (14.5)	19/103 (18.4)
Concentration problems (Q3PC questionnaire ^b), No./total (%)	20/150 (13.3)	18/102 (17.6)
Dyspnea, n (%)	77 (43.5)	0 (0.00)

COPD: chronic obstructive pulmonary disease, **ECMO:** extracorporeal membrane oxygenation, **HIV:** human immunodeficiency virus, **ICU:** intensive care unit, **PY:** pack year, **TC:** telephone consultation

^a Signs were declared as newly-onset during, since or after hospitalization for COVID-19 and persistent at the time of telephone assessment

^b The range, direction and characteristics of the Q3PC questionnaire can be found in Supp Table 1

Supplementary table 4. Baseline and hospitalization characteristics of the patients who had the telephone assessment classified by symptoms triggering the visit to the outpatient facility

	Persistent neuro-cognitive symptoms (n=44)	Persistent respiratory symptoms (n=27)	Abnormal CT-scan (n=15)
Age, years	58.3 (14.1) 26 (59.1) / 18 (40.9)	58.4 (17.9) 18 (66.7) / 9 (33.3)	58.1 (12.0) 7 (46.7) / 8 (53.3)
Women/men No. (%)			
Body mass index, kg/m², mean (SD) [No.]	29.1 (4.9) [42]	29.9 (5.5) [27]	27.7 (6.9) [15]
Comorbidities, No. (%)			
Hypertension	16 (36.4)	12 (44.4)	5 (33.3)
Obesity, No./total (%)	16/42 (38.1)	11/27 (40.7)	4/15 (26.7)
Diabetes mellitus	11 (25.0)	8 (29.6)	2 (13.3)
Chronic cardiac disease	4 (9.1)	2 (7.4)	1 (6.7)
Respiratory disease (other than COPD)	7 (15.9)	4 (14.8)	4 (26.7)
Chronic kidney disease	2 (4.6)	1 (3.7)	0 (0)
Declared psychiatric disorder	3 (6.82)	3 (11.1)	0 (0)
Neurodegenerative disorder	1 (2.3)	1 (3.7)	0 (0)
Alcohol abuse, No./total (%)	4/42 (9.5)	0/25 (0)	2/15 (13.3)
Active cancer	2 (4.6)	1 (3.7)	1 (6.7)
Other immunosuppression	0 (0)	1 (3.7)	2 (13.3)
COPD	3 (6.8)	3 (11.1)	0 (0)
Chronic dialysis	1 (2.3)	0 (0)	0 (0)
HIV infection	2 (4.6)	0 (0)	0 (0)
Solid organ transplantation	1 (2.3)	0 (0)	1 (6.7)
Liver disease	2 (4.6)	0 (0)	2 (13.3)
Pregnancy	0 (0)	0 (0)	0 (0)
Bone marrow transplantation	0 (0)	0 (0)	0 (0)
Smoking, No./total (%)			
No (<5 PY)	33/42 (78.6)	23/25 (92.0)	13/15 (86.7)
Former (> 5 PY)	5/42 (11.9)	1/25 (4.00)	1/15 (6.7)
Active	4/42 (9.5)	1/25 (4.00)	1/15 (6.7)
Specific treatments, No. (%)			
Azithromycin	13 (29.5)	6 (22.2)	7 (46.7)
Tocilizumab (anti-IL6)	2 (4.6)	3 (11.1)	1 (6.7)
Hydroxychloroquine	1 (2.3)	1 (3.7)	0 (0)
Corticosteroids	0 (0)	0 (0)	0 (0)
Lopinavir/Ritonavir	1 (2.3)	1 (3.70)	2 (13.3)
Anakinra (anti-IL1RA)	1 (2.3)	0 (0)	0 (0)
Remdesivir	2 (4.6)	1 (3.7)	2 (13.3)
Pressors use	0 (0)	0 (0)	0 (0)
Therapeutic anticoagulation	10 (22.7)	9 (33.3)	2 (13.3)

Supplementary table 4 (continued)	Persistent neuro-cognitive symptoms (n=44)	Persistent respiratory symptoms (n=27)	Abnormal CT-scan (n=15)
Pulmonary embolism during hospitalization, n (%)	9 (20.5)	7 (25.9)	1 (6.7)
Acute kidney injury during hospitalization, n (%)	6 (13.6)	3 (11.1)	4 (26.7)
Hospitalization in ICU, No. (%)	0 (0)	0 (0)	0 (0)
Duration of ICU stay, days [Q1;Q3]	0 [0;0]	0 [0;0]	0 [0;0]
Total duration of hospitalization, days [Q1;Q3]	6 [3;11]	6 [3;13]	9 [6;11]

Data are presented as No. (%), mean (SD) or median [Q1;Q3]. COPD: chronic obstructive pulmonary disease, ECMO: extracorporeal membrane oxygenation, HIV: human immunodeficiency virus, ICU: intensive care unit, PY: pack year.

Supplementary table 5. Results of the telephone assessment and of the ambulatory visit depending on age (< 75 vs. ≥ 75 yr)

	All patients (n=478)	Patients <75 yr, (n=382)	Patients ≥75 yr, (n=96)	
Telephone assessment				
Delay between hospital discharge and telephone assessment, days [Q1;Q3] (No.)				
Anosmia ^a , n(%)	113 [94;128] (435)	112 [95;127] (352)	113 [93;132] (90)	
Headaches ^a , No./total (%)	25/419 (6.0)	24/335 (7.2)	1/84 (1.2)	
Paresthesia ^a , No./total (%)	23/420 (5.5)	22/334 (6.6)	1/86 (1.2)	
Anorexia ^a , No./total (%)	51/421 (12.1)	46/335 (13.7)	5/86 (5.8)	
Fatigue ^a , No./total (%)	34/436 (7.8)	25/348 (7.2)	9/88 (10.2)	
Weight loss >5% baseline weight ^a , No./total (%)	134/431 (31.1)	111/344 (32.3)	23/87 (26.4)	
Chest discomfort/pain ^a , No./total (%)	31/342 (9.1)	28/286 (9.8)	3/56 (5.4)	
Cough ^a , No./total (%)	34/419 (8.1)	33/332 (9.9)	1/86 (1.2)	
Limb palsy ^a , No./total (%)	40/419 (9.6)	19/335 (5.7)	2/85 (2.4)	
Memory difficulties (Q3PC questionnaire ^b), No./total (%)	28/334 (8.4)	12/85 (14.1)		
Mental slowness (Q3PC questionnaire ^b), No./total (%)	73/416 (17.5)	55/332 (16.6)	18/84 (21.4)	
Concentration problems (Q3PC questionnaire ^b), No./total (%)	42/415 (10.1)	32/331 (9.7)	10/84 (11.9)	
Dyspnea ^a , No./total (%)	41/412 (9.95)	31/331 (9.42)	78 (16.3)	10/84 (12)
Ambulatory visit	75/329 (19.6)	3/83 (3.1)		
Delay between hospital discharge and ambulatory visit, days [Q1;Q3] (No.)				
126 [107;144] (157)	125 [106;144] (143)	132 [108;150] (14)		
Respiratory assessment				
mmRC scale for dyspnea [Q1;Q3] (No.)	1 [1;2] (115)	1 [1;2] (108)	3 [2;3] (7)	
Cough, No./total (%)	23/172 (13.4)	22/158 (13.9)	1/14 (7.1)	
6-min walk test, median [IQR], m, (No.)	462 [380;507] (161)	474 [397;510] (149)	248 [186;305] (12)	
Abnormal lung CT scan, No./total (%)	108/170 (63.2)	94/157 (59.9)	14/14 (100)	
Persistent ground glass opacities, No./total (%)	72/170 (42.4)	64/156 (41)	8/14 (57.1)	
Lung fibrotic lesions, No./total (%)	33/170 (19.4)	30/156 (19.2)	3/14 (21.4)	
FEV1 (expressed as % of theory) [Q1;Q3] (No.)	92 [80;102] (157)	92 [80;102] (151)	86.3 [75;106] (6)	

Supplemental table 5 (continued)	All patients (n=478)	Patients <75 yr, (n=382)	Patients ≥ 75 yr, (n=96)
FEV1/FVC [Q1;Q3] (No.)	83 [79;87] (157)	83 [79;86] (157)	85 [77;91] (7)
TLC (expressed as % of theory), mean (SD), [No.]	83(15.3) [149]	83 (15.2) [144]	80 (17.4) [5]
DLCO < 70, No./total (%)	33/152 (21.7)	31/149 (20.8)	2/3 (66.7)
Echocardiography assessment			
RV dilation on echocardiography, No./total (%)	20/79 (25.3)	19/77 (24.7)	1/2 (50)
LVEF 40-50% on echocardiography ^c , No./total (%)	10/83 (12.0)	10/81 (12.3)	0/2 (0)
Supplementary table 2 (continued)			
Neurological and psychological assessment^{a, b}			
Cognitive complaint (impaired McNair score and/or who reported cognitive symptoms), No./total (%)	79/159 (49.7)	78/150 (52.0)	1/9 (11.1)
Cognitive impairment (impairment of either MoCA or d2-R scores), No./total (%)	61/159 (38.4)	59/150 (39.3)	2/9 (22.2)
Symptoms of anxiety (HADS-Anxiety scale), No./total (%)	53/169 (31.4)	50/156 (32.1)	3/13 (23.1)
Symptoms of depression (BDI test), No./total (%)	35/170 (20.6)	31/157 (19.7)	4/13 (30.8)
Insomnia (ISI score), No./total (%)	90/168 (53.6)	82/155 (52.9)	8/13 (61.5)
Symptoms of PTSD (PCL-5 score), No./total (%)	24/169 (14.2)	22/156 (14.1)	2/13 (15.4)

CT: computed tomography, DLCO: diffusing capacity of the lungs for carbon monoxide, FEV1: forced expiratory volume in one second, FVC: forced vital capacity, ICU: intensive care unit, LVEF: left ventricular ejection fraction, PTSD: post-traumatic stress disorder, RV: right ventricular, TLC: total lung capacity.

^a Signs were declared as newly-onset during, since or after hospitalization for COVID-19 and per the time of assessment at the outpatient facility.

^b The range, direction and characteristics of the McNair, MoCA and d2R scores, of the HADS-Anxiety of the BDI test, and of the ISI and PCL-5 scores can be found in Supp Table 1.

^c No patient had an LVEF <40%.

Supplementary table 6. Results of the telephone assessment classified by symptoms triggering the visit to the outpatient facility

	Persistent neuro-cognitive symptoms (n=44)	Persistent respiratory symptoms (n=27)	Abnormal CT -scan (n=15)
Time from hospital discharge to teleconsultation, days median [Q1;Q3] (No.)	119 [103;131]	111 [104;130]	120 [102;126]
Anosmia ^a , No./total (%)	5/44 (11.4)	5/27 (18.5)	3/15 (20.0)
Headaches ^a , No./total (%)	11/44 (25.0)	5/27 (18.5)	2/15 (13.3)
Paresthesia ^a , No./total (%)	18/44 (40.9)	9/27 (33.3)	5/15 (33.3)
Memory difficulties ^a (Q3PC questionnaire ^b), No./total (%)	24/44 (54.5)	11/27 (40.7)	5/15 (33.3)
Mental slowness ^a (Q3PC questionnaire ^b), No./total (%)	16/44 (36.4)	6/27 (22.2)	4/15 (26.7)
Concentration problems ^a (Q3PC questionnaire ^b), No./total (%)	14/43 (32.6)	7/27 (25.9)	2/15 (13.3)
Abnormal persistent or new dyspnea, n (%)	22 (50.0)	13 (48.1)	6 (40.0)

^a Signs were declared as newly-onset during, since or after hospitalization for COVID-19 and persistent at the time of assessment at telephone assessment.

^b The range, direction and characteristics of the Q3PC questionnaire can be found in Supp Table 1.

Supplementary table 7. Results of the ambulatory visit classified by symptoms triggering the visit to the outpatient facility

	Persistent neurological symptoms (n=44) ^d	Persistent respiratory symptoms (n=27) ^d	Abnormal CT-scan (n=15) ^d
Time from hospital discharge to ambulatory visit, days, median [Q1;Q3] (No.)	139 [119;154] (38)	130 [116;147] (26)	144 [117;156] (14)
Respiratory assessment^a			
mMRC scale for dyspnea ^a , median [Q1;Q3] (No.)	1.0 [1.0;2.0] (37)	2.0 [1.0;2.0] (22)	1.0 [1.0;2.0] (15)
Persisting cough ^a , No./total (%)	9/43 (20.9)	7/26 (26.9)	2/15 (13.3)
6-min walk test, median [IQR], m, (No.)	651 [585;712] (42)	390 [330;480] (23)	462 [381-542] (14)
Abnormal lung CT scan, No./total (%)	18/42 (42.9)	10/26 (38.5)	10/15 (66.7)
Persisting ground glass opacities No./total (%)	12/42 (28.6)	8/25 (32.0)	6/15 (40.0)
Lung fibrotic lesions, No./total (%)	2/42 (4.76)	3/25 (12.0)	0/15(0)
FEV1 (expressed as % of theory), median [Q1;Q3] (No.)	91 [79;102] (35)	92 [81;99] (23)	101 [94;104] (12)
FEV1/FVC, median [Q1;Q3] (No.)	80 [77;86] (35)	83 [77;87] (23)	82 [80;84] (12)
TLC (expressed as % of theory)	85 (12.0) [34]	88 (10.7) [22]	88 (12.8)
DLCO <70%, No./total (%)	2 (6.1) (33)	3/22 (13.6)	0/12 (0)
Echocardiography assessment			
RV dilation on echocardiography, No./total (%)	2/4 (50.0)	0/2 (0)	
LVEF 40-50% on echocardiography ^b , No./total (%)	0/4 (0)	0/2 (0)	
Neurological and psychic assessment^{a,c}			
Cognitive complaint (impaired McNair score and/or reported cognitive symptoms), No./total (%)	26/40 (65)	11/22 (50)	7/15 (46.7)
Cognitive impairment (impairment of either MoCA or d2-R scores), No./total (%)	14/40 (35.0)	6/22 (27.3)	6/15 (40.0)
Symptoms of anxiety (HADS-Anxiety scale), No./total (%)	19/40 (47.5)	10/23 (43.5)	4/15 (26.7)
Symptoms of depression (BDI test), No./total (%)	15/40 (37.5)	10/23 (43.5)	3/15 (20.0)
Insomnia (ISI score), No./total (%)	29/40 (72.5)	15/23 (65.2)	12/15 (80.0)
Symptoms of PTSD (PCL-5 score), No./total (%)	14/40 (35.0)	7/23 (30.4)	2/15 (13.3)

CT: computed tomography, DLCO: diffusing capacity of the lungs for carbon monoxide, FEV1: forced expiratory volume in one second, FVC: forced vital capacity, ICU: intensive care unit, LVEF: left ventricular ejection fraction, PTSD: post-traumatic stress disorder, RV: right ventricular, TLC: total lung capacity

^a Signs were declared as newly-onset during, since or after hospitalization for COVID-19 and persistent at the time of assessment at the outpatient facility.

^b No patient had an LVEF <40%.


^c The range, direction and characteristics of the McNair, MoCA and d2R scores, of the HADS-Anxiety scale, of the BDI test, and of the ISI and PCL-5 scores can be found in Supp Table 1.

^d Ninety-one patients who completed the in-person assessment had a different trigger for the visit.

Supplementary figure 1. Visualization of symptoms* and their overlap presented by the 192 patients** (out of 478 patients) who presented at least one symptom at teleconsultation

* Symptoms which did not exist before COVID-19.

** Fifty-two patients had a new symptom that was not dyspnea, cognitive symptom, or neurological symptom.




Supplementary figure 2. Results of the 36-item Short-Form Health Survey (SF-36) and Multidimensional Fatigue Inventory (MFI-20 scale) scores of the patients admitted to the outpatient clinic

- A. In all patients who completed the questionnaires (n=130 for SF-36 and n=145 for MFI-20)
- B. In patients who had been hospitalized in intensive care unit (ICU, red line, n=68 for SF36 and n=75 for MFI20) or not (non-ICU blue line, n=62 for SF-36 and n=70 for MFI-20).
- C. In patients who had been intubated (red line, n=36 for SF-36 and n=37 for MFI-20) or not (blue line, n=94 for SF-36 and n=108 for MFI-20)
- D. In patients who received vasopressors (red line, n=36 for SF-36 and n=37 for MFI-20) or not (blue line, n=94 for SF-36 and n=108 for MFI-20)
- E. In patients who underwent ECMO (red line, n=6 for SF-36 and n=7 for MFI20) or not (blue line, n=124 for SF-36 and n=138 for MFI-20).

The MFI20 questionnaire evaluates four domains: "general fatigue", "reduced activity", "motivation" and "mental fatigue". Each subscale ranges from 1 to 5, corresponding to the best and worst feeling due to fatigue for each domain, respectively.¹⁰




The SF36 questionnaire evaluates 8 domains: "physical functioning", "role limitations due to physical health", "role limitations due to emotional problems", "energy/fatigue", "emotional well-being", "social functioning", "pain" and "general health". Each subscale ranges from 0 to 100, corresponding to the worst and best health state, respectively⁹.



Supplementary figure 3. Anti-SARS-CoV-2 serological index of the patients admitted to the outpatient clinic

- Panel A: depending on whether patients had been intubated or not during the initial hospitalization
- Panel B: depending on the immunocompromised status
- Panel C: depending on whether patients had been hospitalized in an intensive care unit (ICU) during the initial hospitalization.

(HIV: human immunodeficiency virus, ICU: intensive care unit).



References

1. Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. *American journal of respiratory and critical care medicine*. 2019;200(8):e70-e88.
2. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. *The European respiratory journal*. 2005;26(3):511-522.
3. Graham BL, Brusasco V, Burgos F, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. *Eur Respir J*. 2017;49(1).
4. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *The European respiratory journal*. 2012;40(6):1324-1343.
5. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). *The European respiratory journal*. 1993;6 Suppl 16:41-52.
6. Lewis RA, Howell JB. Definition of the hyperventilation syndrome. *Bull Eur Physiopathol Respir*. 1986;22(2):201-205.
7. Boulding R, Stacey R, Niven R, Fowler SJ. Dysfunctional breathing: a review of the literature and proposal for classification. *Eur Respir Rev*. 2016;25(141):287-294.
8. Metral M, Nadin I, Locatelli I, et al. How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population? *HIV Med*. 2020;21(5):342-348.
9. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992;30(6):473-483.
10. Gentile S, Delaroziere JC, Favre F, Sambuc R, San Marco JL. Validation of the French 'multidimensional fatigue inventory' (MFI 20). *Eur J Cancer Care (Engl)*. 2003;12(1):58-64.
11. Aalto AM, Elovainio M, Kivimaki M, Uutela A, Pirkola S. The Beck Depression Inventory and General Health Questionnaire as measures of depression in the general population: a validation study using the Composite International Diagnostic Interview as the gold standard. *Psychiatry Res*. 2012;197(1-2):163-171.
12. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. *Psychol Med*. 1997;27(2):363-370.
13. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. *J Trauma Stress*. 2015;28(6):489-498.
14. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep Med*. 2001;2(4):297-307.
15. Nasreddine ZS, Patel BB. Validation of Montreal Cognitive Assessment, MoCA, Alternate French Versions. *Can J Neurol Sci*. 2016;43(5):665-671.
16. Poitrenaud J, Kalafat M, Israel L, Guez D. [A critical review of available tools for evaluating memory enhancers in Alzheimer's disease]. *Rev Med Interne*. 1997;18(1):59-71.
17. Brickenkamp R, Schmidt-Atzert L, Liepmann D. *Aufmerksamkeits- und Konzentrationstest*. 2010.

1 Collaborators

- 2 1. Dr. Antoine BALDACCI, Université Paris-Saclay, AP-HP, Service de psychiatrie, Hôpital de Bicêtre, DMU 11 psychiatrie, santé mentale,
3 addictologie et nutrition, équipe MOODS, INSERM U1178, CESP (Centre de Recherche en Épidémiologie et Santé des Populations), Le
4 Kremlin-Bicêtre, France
- 5 2. Dr. Maryne BALLERINI, Université Paris-Saclay, AP-HP, Service de psychiatrie, Hôpital de Bicêtre, DMU 11 psychiatrie, santé mentale,
6 addictologie et nutrition, équipe MOODS, INSERM U1178, CESP (Centre de Recherche en Épidémiologie et Santé des Populations), Le
7 Kremlin-Bicêtre, France
- 8 3. Dr. Aurore BOUGAREL, Université Paris-Saclay, AP-HP, Service de psychiatrie, Hôpital de Bicêtre, DMU 11 psychiatrie, santé mentale,
9 addictologie et nutrition, équipe MOODS, INSERM U1178, CESP (Centre de Recherche en Épidémiologie et Santé des Populations), Le
10 Kremlin-Bicêtre, France
- 11 4. Dr. Theo FAULET, Université Paris-Saclay, AP-HP, Service de psychiatrie, Hôpital de Bicêtre, DMU 11 psychiatrie, santé mentale,
12 addictologie et nutrition, équipe MOODS, INSERM U1178, CESP (Centre de Recherche en Épidémiologie et Santé des Populations), Le
13 Kremlin-Bicêtre, France
- 14 5. Dr. Christian KONDARJIAN, Université Paris-Saclay, AP-HP, Service de psychiatrie, Hôpital de Bicêtre, DMU 11 psychiatrie, santé mentale,
15 addictologie et nutrition, équipe MOODS, INSERM U1018, CESP (Centre de Recherche en Épidémiologie et Santé des Populations), Le
16 Kremlin-Bicêtre, France
- 17 6. Dr. Paul THOREY, Université Paris-Saclay, AP-HP, Service de psychiatrie, Hôpital de Bicêtre, DMU 11 psychiatrie, santé mentale,
18 addictologie et nutrition, équipe MOODS, INSERM U1018, CESP (Centre de Recherche en Épidémiologie et Santé des Populations), Le
19 Kremlin-Bicêtre, France
- 20 7. Prof. Jacques DURANTEAU, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
21 réanimation, douleur, Le Kremlin-Bicêtre, France
- 22 8. Dr. Marie WERNER, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
23 réanimation, douleur, Le Kremlin-Bicêtre, France
- 24 9. Dr. Benjamin BERGIS, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
25 réanimation, douleur, Le Kremlin-Bicêtre, France
- 26 10. Dr. Pierre-Antoine OILLIC, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
27 réanimation, douleur, Le Kremlin-Bicêtre, France
- 28 11. Dr. Christian LAPLACE, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
29 réanimation, douleur, Le Kremlin-Bicêtre, France
- 30 12. Dr. Marie-Josée CABALLERO, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
31 réanimation, douleur, Le Kremlin-Bicêtre, France
- 32 13. Dr. Bernard VIGUE, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
33 réanimation, douleur, Le Kremlin-Bicêtre, France
- 34 14. Dr. Pierre-Etienne LEBLANC, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
35 réanimation, douleur, Le Kremlin-Bicêtre, France
- 36 15. Dr. Guillaume DUBREUIL, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
37 réanimation, douleur, Le Kremlin-Bicêtre, France
- 38 16. Dr. Jonas POCHARD, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
39 réanimation, douleur, Le Kremlin-Bicêtre, France
- 40 17. Dr. Gaelle CHEISSON, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
41 réanimation, douleur, Le Kremlin-Bicêtre, France
- 42 18. Dr. Lucille WILDENBERG, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
43 réanimation, douleur, Le Kremlin-Bicêtre, France
- 44 19. Dr. Aurore RODRIGUES, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
45 réanimation, douleur, Le Kremlin-Bicêtre, France
- 46 20. Dr. Zina BOUZIT, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
47 réanimation, douleur, Le Kremlin-Bicêtre, France
- 48 21. Dr. Claire MENGELE, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
49 réanimation, douleur, Le Kremlin-Bicêtre, France
- 50 22. Dr. Antonia BLANIE, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
51 réanimation, douleur, Le Kremlin-Bicêtre, France
- 52 23. Dr. Karl KAMEL, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation,
53 douleur, Le Kremlin-Bicêtre, France
- 54 24. Dr. Manon SEGURET, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
55 réanimation, douleur, Le Kremlin-Bicêtre, France
- 56 25. Dr. Laurent MARTIN, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie,
57 réanimation, douleur, Le Kremlin-Bicêtre, France

26. Dr. Jacques de MONTBLANC, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

27. Dr. Laurent AUBERT, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

28. Dr. Christine FESSENMEYER, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

29. Dr. Antoine BAUMAN, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

30. Dr. Mostafa MAZBOUDI, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

31. Dr. Yannis BORNEMANN, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

32. Dr. Virginie TARAZONA, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

33. Dr. Faiza MALEK, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

34. Dr. Anne-Claire de CROUY, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

35. Dr. Marie BRUYERE, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

36. Dr. Catherine BAUJARD, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

37. Mrs. Caroline BOYER, Université Paris-Saclay, AP-HP, Service de gynécologie-obstétrique maternité, Hôpital de Bicêtre, DMU 2 Santé des femmes et des nouveaux nés, Le Kremlin-Bicêtre, France

38. Mrs. Alessandra CONTI, Université Paris-Saclay, AP-HP, Service de gynécologie-obstétrique maternité, Hôpital de Bicêtre, DMU 2 Santé des femmes et des nouveaux nés, Le Kremlin-Bicêtre, France

39. Mrs. Anne ELBAZ, Université Paris-Saclay, AP-HP, Service de neurochirurgie, Hôpital de Bicêtre, DMU 9 Neurosciences, Le Kremlin-Bicêtre, France

40. Mrs. Laurence GEFFROY, Université Paris-Saclay, AP-HP, Service de gastro-entérologie, Hôpital de Bicêtre, DMU 6 Maladies et oncologie digestive- nutrition- transplantations, Le Kremlin-Bicêtre, France

41. Mrs. Isabelle HARDY-LÉGER, Université Paris-Saclay, APHP, Service de médecine interne et immunologie clinique, Hôpital de Bicêtre, DMU7 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France

42. Mrs. Ivana KOSIC, Université Paris-Saclay, AP-HP, unité de suites et de réadaptation, Hôpital de Bicêtre, DMU7 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France

43. Mrs. Cécilia ORBLIN-BEDOS, Université Paris-Saclay, AP-HP, Service de néphrologie transplantation, Hôpital de Bicêtre, DMU 4 CORREVE, Maladies du Cœur et des Vaisseaux, Le Kremlin-Bicêtre, France

44. Mrs. Claire PARISOT, Université Paris-Saclay, AP-HP, Service de rééducation neurologique infantile, Hôpital de Bicêtre, DMU 3 Santé de l'enfant et de l'adolescent, Équipe "Psychiatrie du développement", INSERM U1018, CESP (Centre de Recherche en Epidémiologie et Santé des Populations), Le Kremlin-Bicêtre, France

45. Mrs. Julie VIGNERAS, Université Paris-Saclay, AP-HP, Service de rééducation neurologique infantile, Hôpital de Bicêtre, DMU 3 Santé de l'enfant et de l'adolescent, Équipe "Psychiatrie du développement", INSERM U1018, CESP (Centre de Recherche en Epidémiologie et Santé des Populations), Le Kremlin-Bicêtre, France

46. Mr. François RADIGUER, Université Paris-Saclay, AP-HP, Service de réanimation chirurgicale, Hôpital de Bicêtre, DMU 12 Anesthésie, réanimation, douleur, Le Kremlin-Bicêtre, France

47. Mrs. Louise RECHTMAN, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale. DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France

48. Mrs. Marine SOUCIN, Université Paris-Saclay, AP-HP, Equipe de liaison et soins en addictologie, Hôpital de Bicêtre, DMU 11 Psychiatrie, santé mentale, addictologie et nutrition, Le Kremlin-Bicêtre, France

49. Mrs. Yael STORCH, Université Paris-Saclay, AP-HP, service de pneumologie, Hôpital de Bicêtre, DMU 5 Thorinno, Le Kremlin-Bicêtre, France

50. Mrs. Sabine SPORTOUCH, Université Paris-Saclay, AP-HP, service de médecine intensive-réanimation, hôpital de Bicêtre, DMU CORREVE Maladies du cœur et des vaisseaux, Le Kremlin-Bicêtre, France

51. Mrs. Leslie TCHETCHENIGBO, Université Paris-Saclay, AP-HP, Service de psychiatrie, Hôpital de Bicêtre, DMU 11 psychiatrie, santé mentale, addictologie et nutrition, équipe MOODS, Le Kremlin-Bicêtre, France

52. Mrs. Mylène YAM, Université Paris-Saclay, Service de neurophysiologie clinique et épileptologie, Hôpital de Bicêtre, DMU 9 Neurosciences, Le Kremlin-Bicêtre, France

53. Prof. Pierre TISSIERES, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre, DMU 3 Santé de l'enfant et de l'adolescent, Institute of Integrative Biology of the Cell, CNRS, CEA, Le Kremlin-Bicêtre, France

- 116 54. Dr. Clémence MARAIS, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre,
117 DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 118 55. Dr. Caroline CLAUDE, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre,
119 DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 120 56. Dr. Nada SEMAAN, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre, DMU
121 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 122 57. Dr. Ramy CHARBEL, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre, DMU
123 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 124 58. Dr. Narjess GHALI, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre, DMU
125 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 126 59. Dr. Vladimir COUSIN, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre, DMU
127 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 128 60. Dr. Quitterie LAUDOUARD, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre,
129 DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 130 61. Dr. Simon BARREAU, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre,
131 DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 132 62. Dr. Brendan TRAVERT, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre,
133 DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 134 63. Dr. Jean-Eudes PILOQUET, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre,
135 DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 136 64. Dr. Zoé DEMAILLY, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4 CORREVE
137 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 138 65. Dr. Zied MERCHAOUI, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre,
139 DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 140 66. Dr. Philippe DURAND, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre,
141 DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 142 67. Dr. Jordi MIATELLO, Université Paris-Saclay, AP-HP, Service de réanimation pédiatrique et médecine néonatale, Hôpital de Bicêtre, DMU
143 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France
- 144 68. Prof. Christian RICHARD, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4 CORREVE
145 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 146 69. Prof. Jean-Louis TEBOUL, Université Paris-Saclay, AP-HP, service de médecine intensive-réanimation, hôpital de Bicêtre, DMU CORREVE
147 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 148 70. Dr. Nadia ANGUEL, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU CORREVE
149 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 150 71. Dr. David OSMAN, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4 CORREVE
151 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 152 72. Dr. Laurent GUERIN, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4 CORREVE
153 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 154 73. Dr. Soufia AYED, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4 CORREVE
155 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 156 74. Dr. Arthur PAVOT, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4 CORREVE
157 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 158 75. Dr. Astrid BERTIER, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4 CORREVE
159 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 160 76. Dr. Thibault CREUTIN, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4 CORREVE
161 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 162 77. Dr. Christopher LAI, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4 CORREVE
163 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 164 78. Dr. Pierre de NORMANDIE, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4
165 CORREVE Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 166 79. Dr. Benoît GILLE, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4 CORREVE
167 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 168 80. Dr. Anne GRUNENWALD, Université Paris-Saclay, AP-HP, Service de médecine intensive-réanimation, hôpital de Bicêtre, DMU 4 CORREVE
169 Maladies du cœur et des vaisseaux, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 170 81. Prof. Anne-Marie ROQUE-AFONSO, Université Paris-Saclay, AP-HP, Service de virologie, Hôpital Paul Brousse, DMU 15 Biologie-
171 Génétique-PUI, INSERM 1193, Villejuif, France

- 172 82. Dr. Coralie PALLIER, Université Paris-Saclay, AP-HP, Service de virologie, Hôpital Paul Brousse, DMU 15 Biologie-Génétique-PUI, INSERM
173 1193, Villejuif, France
- 174 83. Dr. Christelle VAULOUF-FELLOUS, Université Paris-Saclay, AP-HP, Service de virologie, Hôpital Paul Brousse, DMU 15 Biologie-Génétique-
175 PUI, INSERM 1193, Villejuif, France
- 176 84. Dr. Lina MOUNA, Université Paris-Saclay, AP-HP, Service de virologie, Hôpital Paul Brousse, DMU 15 Biologie-Génétique-PUI, INSERM
177 1193, Villejuif, France
- 178 85. Dr. Honorine FENAUX, Université Paris-Saclay, AP-HP, Service de virologie, Hôpital Paul Brousse, DMU 15 Biologie-Génétique-PUI,
179 INSERM 1193, Villejuif, France
- 180 86. Dr. Nicolas FORTINEAU, Université Paris-Saclay, AP-HP, Service de microbiologie, Hôpital de Bicêtre, DMU 15 Biologie-Génétique-PUI,
181 INSERM 1193, Le Kremlin-Bicêtre, France
- 182 87. Dr. Cécile EMERAUD, Université Paris-Saclay, AP-HP, Service de microbiologie, Hôpital de Bicêtre, DMU 15 Biologie-Génétique-PUI,
183 INSERM 1193, Le Kremlin-Bicêtre, France
- 184 88. Dr. Mona KHECHAREM, Université Paris-Saclay, AP-HP, Service de microbiologie, Hôpital de Bicêtre, DMU 15 Biologie-Génétique-PUI,
185 INSERM 1193, Le Kremlin-Bicêtre, France
- 186 89. Dr. Souad OUZANI, Université Paris-Saclay, AP-HP, Service de microbiologie, Hôpital de Bicêtre, DMU 15 Biologie-Génétique-PUI, INSERM
187 1193, Le Kremlin-Bicêtre, France
- 188 90. Dr. Gaelle CUZON, Université Paris-Saclay, AP-HP, Service de microbiologie, Hôpital de Bicêtre, DMU 15 Biologie-Génétique-PUI, INSERM
189 1193, Le Kremlin-Bicêtre, France
- 190 91. Dr. Samer SOLIMAN, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU 14
191 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 192 92. Dr. Hugo GORTAIS, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU 14
193 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 194 93. Dr. Florian MAXWELL, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU
195 14 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 196 94. Dr. Alexia SAVIGNAC, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU
197 14 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 198 95. Dr. Matthieu DEVILDER, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU
199 14 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 200 96. Dr. Miryam MOUSSA, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU
201 14 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 202 97. Dr. Alfredo CANTARINHA, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre,
203 DMU 14 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 204 98. Dr. Alain ABDO, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU 14 Smart
205 Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 206 99. Dr. Roberta RUSSO, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU 14
207 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 208 100. Dr. Guillaume CLUZEL, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU
209 14 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 210 101. Dr. Mathilde GAYET, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU 14
211 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 212 102. Dr. Teodor VASILE, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU 14
213 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 214 103. Dr. Cristina BALASA, Université Paris-Saclay, AP-HP, Service de radiologie diagnostique et interventionnelle, Hôpital de Bicêtre, DMU 14
215 Smart Imaging, BioMaps, Le Kremlin-Bicêtre, France
- 216 104. Prof. Cécile GOUJARD, Université Paris-Saclay, AP-HP, Service de médecine interne et immunologie clinique, Hôpital de Bicêtre, DMU 7
217 Endocrinologie-immunités-inflammations-cancer-urgences, INSERM U1018, CESP (Centre de Recherche en Epidémiologie et Santé des
218 Populations), Le Kremlin-Bicêtre, France
- 219 105. Dr. Christelle CHANTALAT-AUGER, Université Paris-Saclay, AP-HP, Service de médecine interne et immunologie clinique, Hôpital de
220 Bicêtre, DMU 7 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 221 106. Dr. Antoine CHERET, Université Paris-Saclay, AP-HP, Service de médecine interne et immunologie clinique, Hôpital de Bicêtre, DMU 7
222 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 223 107. Dr. Fanny URBAIN, Université Paris-Saclay, AP-HP, Service de médecine interne et immunologie clinique, Hôpital de Bicêtre, DMU 7
224 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 225 108. Dr. Ariane LAPARRA, Université Paris-Saclay, AP-HP, Service de médecine interne et immunologie clinique, Hôpital de Bicêtre, DMU 7
226 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 227 109. Dr. Venceslas BOURDIN, Université Paris-Saclay, AP-HP, Service de médecine interne et immunologie clinique, Hôpital de Bicêtre, DMU
228 7 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France

- 229 110. Dr. Daphné CUVEILLIER, Université Paris-Saclay, AP-HP, Service de médecine interne et immunologie clinique, Hôpital de Bicêtre, DMU
230 7 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 231 111. Dr. Jeremy GOTTLIEB, Université Paris-Saclay, AP-HP, Service de médecine interne et immunologie clinique, Hôpital de Bicêtre, DMU7
232 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 233 112. Dr. Stéphane DIEZ, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
234 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 235 113. Dr. Etienne HINGLAIS, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-
236 immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 237 114. Dr. Christophe VINCENT-CASSY, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-
238 immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 239 115. Dr. Lydie NGUYEN, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
240 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 241 116. Dr. Faraj NIKPAY, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
242 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 243 117. Dr. Jacqueline DEPRET-VASSAL, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-
244 immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 245 118. Dr. Rola STEPHAN, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
246 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 247 119. Dr. Patience JOMO, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
248 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 249 120. Dr. Maryvonne MARINEAU, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-
250 immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 251 121. Dr. Djalila GACEMI, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
252 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 253 122. Dr. Amina SEMATI, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
254 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 255 123. Dr. Ciprian SIMISDEAN, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-
256 immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 257 124. Dr. Yamina DJEBBAR, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-
258 immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 259 125. Dr. Hasna BAYOUB, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
260 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 261 126. Dr. Yves MBEDE, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
262 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 263 127. Dr. Maurice RAPHAEL, Université Paris-Saclay, AP-HP, Service d'accueil des urgences, Hôpital de Bicêtre, DMU 7 Endocrinologie-
264 immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 265 128. Prof. Stéphane JAUREGUILERRY, Université Paris-Saclay, AP-HP, Service des maladies infectieuses et tropicales, Hôpital de Bicêtre, DMU
266 7 Endocrinologie-immunités-inflammations-cancer-urgences, INSERM U1018, CESP (Centre de Recherche en Epidémiologie et Santé des
267 Populations), Le Kremlin-Bicêtre, France
- 268 129. Dr. Rocco COLLARINO, Université Paris-Saclay, AP-HP, Service des maladies infectieuses et tropicales, Hôpital de Bicêtre, DMU 7
269 Endocrinologie-immunités-inflammations-cancer-urgences, INSERM U1018, CESP (Centre de Recherche en Epidémiologie et Santé des
270 Populations), Le Kremlin-Bicêtre, France
- 271 130. Dr. Iryna BUKREYEVA, Université Paris-Saclay, AP-HP, Service des maladies infectieuses et tropicales, Hôpital de Bicêtre, DMU 7
272 Endocrinologie-immunités-inflammations-cancer-urgences, INSERM U1018, CESP (Centre de Recherche en Epidémiologie et Santé des
273 Populations), Le Kremlin-Bicêtre, France
- 274 131. Dr. Lélia ESCAUT, Université Paris-Saclay, AP-HP, Service des maladies infectieuses et tropicales, Hôpital de Bicêtre, DMU 7
275 Endocrinologie-immunités-inflammations-cancer-urgences, INSERM U1018, CESP (Centre de Recherche en Epidémiologie et Santé des
276 Populations), Le Kremlin-Bicêtre, France
- 277 132. Dr. Ouda DERRADJI, Université Paris-Saclay, AP-HP, Service des maladies infectieuses et tropicales, Hôpital de Bicêtre, DMU 7
278 Endocrinologie-immunités-inflammations-cancer-urgences, INSERM U1018, CESP (Centre de Recherche en Epidémiologie et Santé des
279 Populations), Le Kremlin-Bicêtre, France
- 280 133. Prof. Marc HUMBERT, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
281 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 282 134. Prof. Olivier SITBON, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
283 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 284 135. Dr. Sophie BULIFON, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
285 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France

- 286 136. Dr. Céline CHERON, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
287 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 288 137. Dr. Mitja JEVNIKAR, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
289 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 290 138. Dr. Xavier JAÏS, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
291 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 292 139. Dr. Etienne-Marie JUTANT, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre,
293 DMU 5 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 294 140. Dr. Florence PARENT, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
295 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 296 141. Dr. Mariana PREDA, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
297 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 298 142. Dr. Andrei SEFERIAN, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
299 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 300 143. Dr. Sabina SOLINAS, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
301 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 302 144. Dr. Athénaïs BOUCLY, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
303 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 304 145. Dr. Charles FAUVEL, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
305 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 306 146. Dr. Thomas LACOSTE, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
307 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 308 147. Dr. Jérémie PICHON, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
309 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 310 148. Dr. Hélène PRINGUEZ, Université Paris-Saclay, AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital de Bicêtre, DMU 5
311 Thorinno, Inserm UMR_S999, Le Kremlin-Bicêtre, France
- 312 149. Dr. Renaud SNANOUDJ, Université Paris-Saclay, AP-HP, Service de néphrologie transplantation, Hôpital de Bicêtre, DMU 4 CORREVE
313 Maladies du cœur et des vaisseaux, Le Kremlin-Bicêtre, France
- 314 150. Dr. Hélène DOBOSZIEWICZ, Université Paris-Saclay, AP-HP, Service de néphrologie transplantation, Hôpital de Bicêtre, DMU 4 CORREVE
315 Maladies du cœur et des vaisseaux, Le Kremlin-Bicêtre, France
- 316 151. Dr. Matthieu GUILLET, Université Paris-Saclay, AP-HP, Service de néphrologie transplantation, Hôpital de Bicêtre, DMU 4 CORREVE
317 Maladies du cœur et des vaisseaux, Le Kremlin-Bicêtre, France
- 318 152. Dr. Marwa LAIFI, Université Paris-Saclay, AP-HP, Service de néphrologie transplantation, Hôpital de Bicêtre, DMU 4 CORREVE Maladies
319 du cœur et des vaisseaux, Le Kremlin-Bicêtre, France
- 320 153. Dr. Edouard LEFEVRE, Université Paris-Saclay, AP-HP, Service de néphrologie transplantation, Hôpital de Bicêtre, DMU 4 CORREVE
321 Maladies du cœur et des vaisseaux, Le Kremlin-Bicêtre, France
- 322 154. Dr. Alexandre DORMOY, Université Paris-Saclay, AP-HP, Service d'endocrinologie et des maladies de la reproduction, Hôpital de Bicêtre,
323 DMU 7 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 324 155. Dr. Alexandre VIRONE, Université Paris-Saclay, AP-HP, Service de rhumatologie, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
325 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 326 156. Dr. Julien HENRY, Université Paris-Saclay, AP-HP, Service de rhumatologie, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
327 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 328 157. Dr. Gaetane NOCTURNE, Université Paris-Saclay, AP-HP, Service de rhumatologie, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
329 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 330 158. Dr. Stephan PAVY, Université Paris-Saclay, AP-HP, Service de rhumatologie, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-
331 inflammations-cancer-urgences, Le Kremlin-Bicêtre, France
- 332 159. Dr. Christophe BELLANGER Université Paris-Saclay, AP-HP, Service d'uropathie, Hôpital de Bicêtre, DMU 6 Maladies et cancers du foie, de
333 l'appareil digestif et urinaire – transplantation - nutrition, Le Kremlin-Bicêtre, France
- 334 160. Dr. Liza KASSOURI Université Paris-Saclay, AP-HP, Service d'uropathie, Hôpital de Bicêtre, DMU 6 Maladies et cancers du foie, de l'appareil
335 digestif et urinaire – transplantation - nutrition, Le Kremlin-Bicêtre, France
- 336 161. Dr. Lise DURANTEAU, Université Paris-Saclay, AP-HP, Service de gynécologie-obstétrique, Hôpital de Bicêtre, DMU 2 Santé de la Femme
337 et du Nouveau-Né
- 338 162. Dr. Jennifer FLANDRIN, Université Paris-Saclay, AP-HP, Service de gynécologie-obstétrique, Hôpital de Bicêtre, DMU 2 Santé de la Femme
339 et du Nouveau-Né
- 340 163. Dr. Alicia GARNIER, Université Paris-Saclay, AP-HP, Service de gynécologie-obstétrique, Hôpital de Bicêtre, DMU 2 Santé de la Femme et
341 du Nouveau-Né

164. Dr. Adeline NOT, Université Paris-Saclay, AP-HP, Service de neurologie, Hôpital de Bicêtre, DMU 9 Neurosciences, Le Kremlin-Bicêtre, France

165. Dr. Cécile CAUQUIL, Université Paris-Saclay, AP-HP, Service de neurologie, Hôpital de Bicêtre, DMU 9 Neurosciences, Le Kremlin-Bicêtre, France

166. Dr. Céline LABEYRIE, Université Paris-Saclay, AP-HP, Service de neurologie, Hôpital de Bicêtre, DMU 9 Neurosciences, Le Kremlin-Bicêtre, France

167. Dr. Constance RABEL, Université Paris-Saclay, AP-HP, Service de neurologie, Hôpital de Bicêtre, DMU 9 Neurosciences, Le Kremlin-Bicêtre, France

168. Dr. Jérémie BENICHOU, Université Paris-Saclay, AP-HP, Service d'ophtalmologie, Hôpital de Bicêtre, DMU 7 endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France

169. Dr. Cédric LEBACLE, Université Paris-Saclay, AP-HP, Service d'urologie, Hôpital de Bicêtre, DMU 6 Maladies et cancers du foie, de l'appareil digestif et urinaire - transplantation - nutrition, Le Kremlin-Bicêtre, France

170. Dr. Delphine TAUSSIG, Université Paris-Saclay, AP-HP, Service de gériatrie aiguë, Hôpital de Bicêtre, DMU 1 Médecine territoire gériatrie, Le Kremlin-Bicêtre, France

171. Dr. Pauline RABIER-LEBRUN, Université Paris-Saclay, AP-HP, Service de gériatrie aiguë, Hôpital de Bicêtre, DMU 1 Médecine territoire gériatrie, Le Kremlin-Bicêtre, France

172. Dr. Catherine SAGOT, Université Paris-Saclay, AP-HP, Service de gériatrie aiguë, Hôpital de Bicêtre, DMU 1 Médecine territoire gériatrie, Le Kremlin-Bicêtre, France

173. Dr. Mary SOUDANI, Université Paris-Saclay, AP-HP, Service de gériatrie aiguë, Hôpital de Bicêtre, DMU 1 Médecine territoire gériatrie, Le Kremlin-Bicêtre, France

174. Prof. Charles COURT, Université Paris-Saclay, AP-HP, Service de chirurgie orthopédique et traumatologique, Hôpital de Bicêtre, DMU 10 Chirurgie orthopédique-chirurgie plastique-reconstruction, Le Kremlin-Bicêtre, France

175. Dr. Véronique MOLINA, Université Paris-Saclay, AP-HP, Service de chirurgie orthopédique et traumatologique, Hôpital de Bicêtre, DMU 10 Chirurgie orthopédique-chirurgie plastique-reconstruction, Le Kremlin-Bicêtre, France

176. Dr. Charlie BOUTHORS, Université Paris-Saclay, AP-HP, Service de chirurgie orthopédique et traumatologique, Hôpital de Bicêtre, DMU 10 Chirurgie orthopédique-chirurgie plastique-reconstruction, Le Kremlin-Bicêtre, France

177. Prof. Philippe CHANSON, Université Paris-Saclay, AP-HP, Service d'endocrinologie et des maladies de la reproduction, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France

178. Dr. Alexandre DORMOY, Université Paris-Saclay, AP-HP, Service d'endocrinologie et des maladies de la reproduction, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France

179. Dr. Sylvie SALENAYE, Université Paris-Saclay, AP-HP, Service d'endocrinologie et des maladies de la reproduction, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France

180. Dr. Carine RICHA, Université Paris-Saclay, AP-HP, Service d'endocrinologie et des maladies de la reproduction, Hôpital de Bicêtre, DMU 7 Endocrinologie-immunités-inflammations-cancer-urgences, Le Kremlin-Bicêtre, France

181. Dr. Claire BOUVATTIER, Université Paris-Saclay, AP-HP, Service d'endocrinologie et diabète de l'enfant, Hôpital de Bicêtre, DMU 3 Santé de l'enfant et de l'adolescent, INSERM U1185, Le Kremlin-Bicêtre, France

182. Dr. Anya ROTENBUHLER, Université Paris-Saclay, AP-HP, Service d'endocrinologie et diabète de l'enfant, Hôpital de Bicêtre, DMU 3 Santé de l'enfant et de l'adolescent, INSERM U1185, Le Kremlin-Bicêtre, France

183. Dr. Cécile BIBAL, Université Paris-Saclay, AP-HP, Service d'endocrinologie et diabète de l'enfant, Hôpital de Bicêtre, DMU 3 Santé de l'enfant et de l'adolescent, INSERM U1185, Le Kremlin-Bicêtre, France

184. Dr. Guillaume MORELLE, Université Paris-Saclay, AP-HP, Service de pédiatrie polyvalente Hôpital de Bicêtre, DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France

185. Dr. Tamazout GUIDDIR, Université Paris-Saclay, AP-HP, Service de pédiatrie polyvalente Hôpital de Bicêtre, DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France

186. Dr. Martin AUGER, Université Paris-Saclay, AP-HP, Service de pédiatrie polyvalente Hôpital de Bicêtre, DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France

187. Dr. Delphine REGNARD, Université Paris-Saclay, AP-HP, Service de pédiatrie polyvalente Hôpital de Bicêtre, DMU 3 Santé de l'enfant et de l'adolescent, Le Kremlin-Bicêtre, France

188. Dr. Léa GOMEZ Université Paris-Saclay, AP-HP, Service de médecine nucléaire, Hôpital de Bicêtre, DMU 14 Smart imaging, Le Kremlin-Bicêtre, France

189. Dr. Florent BESSON, Université Paris-Saclay, AP-HP, Service de médecine nucléaire, Hôpital de Bicêtre, DMU 14 Smart imaging, Le Kremlin-Bicêtre, France

190. Dr. Marie FRANK, Université Paris-Saclay, AP-HP, Département d'Information Médicale, Hôpital de Bicêtre, DMU 13 Santé Publique – Information Médicale et appui à la recherche clinique, Le Kremlin-Bicêtre, France